Empowered Funds
MGX icon

Empowered Funds’s Metagenomi Therapeutics MGX Stock Holding History

Empowered Funds’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$39.4K Buy
+37,200
New +$44.8K ﹤0.01% 2490

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
RBF Capital
RBF Capital San Francisco, California $2.3B AUM 22.6% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
FAG
Fortitude Advisory Group Gig Harbor, Washington $262M AUM 30.62% 1-Year Est. Return

Empowered Funds's MGX Position: Q3 2026 in Review

Empowered Funds opened a new position in Metagenomi Therapeutics (MGX) in Q3 2026: 37,200 shares worth $39.4K. The stake represents ﹤0.01% of the portfolio and ranks #2490 among its holdings.

27 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

  • Empowered Funds held 37,200 shares of Metagenomi Therapeutics worth $39.4K as of Q3 2026.
  • Metagenomi Therapeutics was a new Empowered Funds position in Q3 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2490 holding.
  • 27 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.